Literature DB >> 21847580

PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.

Chun-Yan Wu1, Zhi-Han Tang, Lu Jiang, Xue-Fei Li, Zhi-Sheng Jiang, Lu-Shan Liu.   

Abstract

This paper investigated the effects of ox-LDL on PCSK9, and the molecular mechanisms of PCSK9 siRNA-inhibited apoptosis induced by ox-LDL in human umbilical vein endothelial cells (HUVECs), to clarify the role of PCSK9 in atherosclerogenesis. HUVECs were incubated with ox-LDL for 24 h. The apoptosis was observed by Hoechst 33258 staining. The expression of PCSK9, LOX-1 mRNAs and proteins was detected by RT-PCR, western blot, respectively. The PCSK9 siRNAs labeled with fluorescence were transfected into HUVECs by Lipofectamine 2000. After transfection for 24 h, cells were treated with ox-LDL for 24 h, HUVECs apoptosis transfected siRNA was detected by Hoechst 33258 staining and flow cytometer. The expression of Bcl-2, Bax, caspase3, 8, 9 was detected by western blot. The activity of caspase3, 9 was detected by kits. Our results showed that apoptosis of HUVECs and the expressions of PCSK9 and LOX-1 were upregulated secondary to induction by ox-LDL in a concentration-dependent manner. However, ox-LDL-induced HUVEC apoptosis and PCSK9 expression, but not LOX-1 expression, were significantly reduced by PCSK9 siRNA. These results demonstrate a linkage between HUVEC apoptosis and PCSK9 expression. Furthermore, we detected the possible pathway involved in apoptotic regulation by PCSK9 siRNA; our results showed that the expression of Bcl-2 decreased, whereas that of Bax increased. In addition, ox-LDL enhanced the activity of caspase9 and then caspase3. Pretreatment of HUVECs with PCSK9 siRNA blocked these effects of ox-LDL. These findings suggest that ox-LDL-induced HUVECs apoptosis could be inhibited by PCSK9 siRNA, in which Bcl/Bax-caspase9-caspase3 pathway maybe was involved through reducing the Bcl-2/Bax ratio and inhibited the activation of both caspase9 and 3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847580     DOI: 10.1007/s11010-011-1028-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

Review 1.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

2.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Authors:  Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2007-01-22       Impact factor: 5.922

3.  The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Paul Holvoet; Nancy S Jenny; Pamela J Schreiner; Russell P Tracy; David R Jacobs
Journal:  Atherosclerosis       Date:  2006-09-18       Impact factor: 5.162

4.  Oxidized low-density lipoprotein induces apoptotic insults to mouse cerebral endothelial cells via a Bax-mitochondria-caspase protease pathway.

Authors:  Tyng-Guey Chen; Ta-Liang Chen; Huai-Chia Chang; Yu-Ting Tai; Yih-Giun Cherng; Ya-Ting Chang; Ruei-Ming Chen
Journal:  Toxicol Appl Pharmacol       Date:  2006-12-06       Impact factor: 4.219

5.  Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells.

Authors:  Jiawei Chen; Jawahar L Mehta; Nezam Haider; Xingjian Zhang; Jagat Narula; Dayuan Li
Journal:  Circ Res       Date:  2003-12-18       Impact factor: 17.367

6.  Role of reactive oxygen species and Bax in oxidized low density lipoprotein-induced apoptosis of human monocytes.

Authors:  Natalia Ermak; Bernard Lacour; Tilman B Drüeke; Stéphanie Vicca
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

7.  Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells.

Authors:  Jizhong Cheng; Ruwen Cui; Chu-Huang Chen; Jie Du
Journal:  Endocrinology       Date:  2007-02-08       Impact factor: 4.736

8.  Targeting PCSK9 for the treatment of hypercholesterolemia.

Authors:  Joseph A Hedrick
Journal:  Curr Opin Investig Drugs       Date:  2009-09

9.  Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Authors:  Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

10.  Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.

Authors:  Christopher J Duff; Martin J Scott; Ian T Kirby; Sue E Hutchinson; Steve L Martin; Nigel M Hooper
Journal:  Biochem J       Date:  2009-05-01       Impact factor: 3.857

View more
  52 in total

Review 1.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.

Authors:  Ashwin Durairaj; Alberto Sabates; Jonathan Nieves; Brian Moraes; Seth Baum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

2.  PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.

Authors:  Ji Soo Lee; Daniel Rosoff; Audrey Luo; Martha Longley; Monte Phillips; Katrin Charlet; Christine Muench; Jeesun Jung; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2019-05-03       Impact factor: 3.455

3.  PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.

Authors:  Ming-Xue Piao; Ji-Wei Bai; Peng-Fei Zhang; Ya-Zhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis.

Authors:  Meaghan D Waltmann; Joshua E Basford; Eddy S Konaniah; Neal L Weintraub; David Y Hui
Journal:  Biochim Biophys Acta       Date:  2014-05-16

Review 5.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

6.  Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.

Authors:  Konstantinos C Koskinas; Stephan Windecker; Aliki Buhayer; Baris Gencer; Giovanni Pedrazzini; Christian Mueller; Stephan Cook; Olivier Muller; Christian M Matter; Lorenz Räber; Dik Heg; François Mach
Journal:  Clin Cardiol       Date:  2018-11-26       Impact factor: 2.882

7.  Activation of sonic hedgehog signaling attenuates oxidized low-density lipoprotein-stimulated brain microvascular endothelial cells dysfunction in vitro.

Authors:  Xiu-Long Jiang; Ting Chen; Xu Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 8.  Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.

Authors:  Angelos D Karagiannis; Martin Liu; Peter P Toth; Shijia Zhao; Devendra K Agrawal; Peter Libby; Yiannis S Chatzizisis
Journal:  Curr Atheroscler Rep       Date:  2018-03-10       Impact factor: 5.113

Review 9.  PCSK9 Inhibitors: potential in cardiovascular therapeutics.

Authors:  Rose Q Do; Robert A Vogel; Gregory G Schwartz
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

10.  Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells.

Authors:  Ying Hu; Hui-Xin Liu; Yuqi He; Yaping Fang; Jianwen Fang; Yu-Jui Yvonne Wan
Journal:  Biochem Pharmacol       Date:  2013-02-08       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.